Innate immune restriction of enveloped virus exit

有包膜病毒退出的先天免疫限制

基本信息

  • 批准号:
    MR/P021735/1
  • 负责人:
  • 金额:
    $ 56.97万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2018
  • 资助国家:
    英国
  • 起止时间:
    2018 至 无数据
  • 项目状态:
    已结题

项目摘要

Viruses that infect the respiratory tract are responsible for a huge number of global deaths every year, especially in vulnerable populations like the malnourished, children and the elderly. Two of the most significant respiratory viruses are RSV (respiratory syncytial virus) and MeV (measles virus). There is no vaccine to RSV and most children will have had this infection by the time they are 2 years old. Unfortunately, around 150,000 children a year die from this disease, mostly because the virus causes pneumonia and other serious infections of the airways. The situation with MeV is more complex because although we have a vaccine it has not been used to fully eradicate the virus. As a result, and because MeV itself is incredibly infectious, around 115,000 people still die from this infection every year. RSV and MeV are therefore important viruses to study in the laboratory and hospital setting. If we can improve our understanding of these viruses we can design better drugs and vaccines to tackle these infections, reducing the strain they place on global healthcare.My research is focused on the immune response to RSV and MeV, especially during the early stages of disease when these viruses are establishing themselves in the human airway. This project is designed to answer medically and scientifically relevant questions such as:1. How does the cell work to fight RSV and MeV infection, in particular when and where are these pathogens targeted for restriction?2. How and why do these viral infections cause disease?3. Why some people are more susceptible than others to these infections?4. Whether the immune response itself can sometimes cause problems?My project will focus on the early acting innate immune system. This is made up of a network of sensors and effectors that have evolved to detect pathogens, like viruses, and inhibit their replication and continued spread. I will examine how RSV and MeV are inhibited by this pathway, focusing on the formation and release of virus particles. This is an important stage in the viral life cycle because it is essential for continued infection. As such, improving our knowledge of this process could lead to the development of targeted antivirals. To be more specific about the experiments we will perform: RSV and MeV steal their envelope, or coat, from the infected cell during a process called budding. This process is reliant on a number of viral proteins that work together to make infectious particles. I have developed high-throughput assays that let me investigate these proteins and the various stages of the viral life-cycle in greater detail. Using these assays I will examine whether individual proteins from the innate immune system can inhibit the formation of new virus particles. Separately I have developed new techniques that allow purification of the cellular membranes where RSV and MeV replicate. I will use this technology to examine what immune proteins are drawn into this fraction during infection. The proteins that I identify will then be characterised to examine how, where and when they work to inhibit these infections. In addition I will investigate their relevance in models of the respiratory tract and also examine whether genetic variation in these proteins affects their function. To summarise; this project will examine and characterise the immune response to RSV and MeV, two important childhood disease of the respiratory tract.
感染呼吸道的病毒每年导致全球大量死亡,特别是在营养不良者、儿童和老年人等脆弱人群中。两种最重要的呼吸道病毒是RSV(呼吸道合胞病毒)和MeV(麻疹病毒)。目前还没有针对RSV的疫苗,大多数儿童在2岁时就会感染这种病毒。不幸的是,每年约有15万名儿童死于这种疾病,主要是因为这种病毒导致肺炎和其他严重的呼吸道感染。MeV的情况更复杂,因为尽管我们有疫苗,但它还没有被用来完全根除病毒。因此,由于MeV本身具有令人难以置信的传染性,每年仍有约11.5万人死于这种感染。因此,RSV和MeV是实验室和医院环境中需要研究的重要病毒。如果我们能够提高对这些病毒的理解,我们就可以设计出更好的药物和疫苗来应对这些感染,减少它们给全球卫生保健带来的压力。我的研究重点是对RSV和MeV的免疫反应,特别是在疾病的早期阶段,当这些病毒进入人类呼吸道时。这个项目旨在回答与医学和科学相关的问题,例如:1.细胞如何工作来对抗RSV和MeV感染,特别是这些病原体何时何地被限制?2.这些病毒感染是如何以及为什么导致疾病的?3.为什么有些人比其他人更容易感染这些感染?4.免疫反应本身有时是否会造成问题?我的项目将专注于早期作用的先天免疫系统。这是由传感器和效应器网络组成的,这些传感器和效应器已经进化到检测病原体,如病毒,并抑制它们的复制和继续传播。我将研究RSV和MeV是如何被这一途径抑制的,重点是病毒颗粒的形成和释放。这是病毒生命周期中的一个重要阶段,因为它对持续感染至关重要。因此,提高我们对这一过程的了解可能会导致靶向抗病毒药物的开发。更具体地说,我们将进行的实验:RSV和MeV在一个称为发芽的过程中从受感染的细胞中窃取它们的包膜或皮毛。这一过程依赖于大量的病毒蛋白,这些蛋白共同作用形成具有感染性的颗粒。我已经开发出高通量分析方法,使我能够更详细地研究这些蛋白质和病毒生命周期的不同阶段。利用这些分析,我将检验来自先天免疫系统的单个蛋白质是否能够抑制新病毒颗粒的形成。另外,我开发了一种新技术,可以对RSV和MeV复制的细胞膜进行纯化。我将使用这项技术来检查在感染过程中哪些免疫蛋白被吸入这一部分。然后,我确定的蛋白质将进行特征描述,以检查它们如何、在哪里以及何时抑制这些感染。此外,我还将研究它们在呼吸道模型中的相关性,并检查这些蛋白质的遗传变异是否会影响它们的功能。总而言之,这个项目将检查和描述对RSV和MeV的免疫反应,这是两种重要的儿童呼吸道疾病。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Respiratory syncytial virus sequesters NF-?B subunit p65 to cytoplasmic inclusion bodies to inhibit innate immune signalling
呼吸道合胞病毒将 NF-κB 亚基 p65 隔离到细胞质包涵体中以抑制先天免疫信号传导
  • DOI:
    10.1101/2020.02.11.944363
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Jobe F
  • 通讯作者:
    Jobe F
Bacterial flagellin promotes viral entry via an NF-kB and Toll Like Receptor 5 dependent pathway
  • DOI:
    10.1038/s41598-019-44263-7
  • 发表时间:
    2019-05-27
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Benedikz, Elizabeth K.;Bailey, Dalan;McKeating, Jane A.
  • 通讯作者:
    McKeating, Jane A.
Structure-Guided Identification of a Nonhuman Morbillivirus with Zoonotic Potential.
  • DOI:
    10.1128/jvi.01248-18
  • 发表时间:
    2018-12-01
  • 期刊:
  • 影响因子:
    5.4
  • 作者:
    Abdullah N;Kelly JT;Graham SC;Birch J;Gonçalves-Carneiro D;Mitchell T;Thompson RN;Lythgoe KA;Logan N;Hosie MJ;Bavro VN;Willett BJ;Heaton MP;Bailey D
  • 通讯作者:
    Bailey D
Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates.
组合F-G免疫原作为NIPAH和呼吸道合胞病毒疫苗候选。
  • DOI:
    10.3390/v13101942
  • 发表时间:
    2021-09-28
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Isaacs A;Cheung STM;Thakur N;Jaberolansar N;Young A;Modhiran N;Bailey D;Graham SP;Young PR;Chappell KJ;Watterson D
  • 通讯作者:
    Watterson D
The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins.
  • DOI:
    10.1371/journal.pbio.3001016
  • 发表时间:
    2020-12
  • 期刊:
  • 影响因子:
    9.8
  • 作者:
    Conceicao C;Thakur N;Human S;Kelly JT;Logan L;Bialy D;Bhat S;Stevenson-Leggett P;Zagrajek AK;Hollinghurst P;Varga M;Tsirigoti C;Tully M;Chiu C;Moffat K;Silesian AP;Hammond JA;Maier HJ;Bickerton E;Shelton H;Dietrich I;Graham SC;Bailey D
  • 通讯作者:
    Bailey D
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dalan Bailey其他文献

Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
  • DOI:
    10.1186/s12879-024-10367-3
  • 发表时间:
    2024-12-28
  • 期刊:
  • 影响因子:
    3.000
  • 作者:
    Doreen Lugano;Bernadette Kutima;Makobu Kimani;Antipa Sigilai;John Gitonga;Angela Karani;Donald Akech;Boniface Karia;Abdhalah K. Ziraba;Angela Maina;Arnold Lambisia;Donwilliams Omuoyo;Daisy Mugo;Ruth Lucinde;Sharon Owuor;Gloria Konyino;Joseph Newman;Dalan Bailey;Eunice Nduati;George Githinji;Charles N. Agoti;Philip Bejon;J. Anthony G. Scott;Ambrose Agweyu;Wangeci Kagucia;George M. Warimwe;Charles Sande;Lynette I. Ochola-Oyier;James Nyagwange
  • 通讯作者:
    James Nyagwange
Identifying an evolutionary origin for morbilliviruses in bats
确定蝙蝠中麻疹病毒的进化起源
  • DOI:
    10.1038/s41564-025-02021-8
  • 发表时间:
    2025-06-04
  • 期刊:
  • 影响因子:
    19.400
  • 作者:
    Dalan Bailey
  • 通讯作者:
    Dalan Bailey
Estimating population immunity to SARS-CoV-2 by random sampling from primary and secondary healthcare in Scotland, May 2024
2024年5月通过对苏格兰初级和二级医疗保健进行随机抽样评估对新冠病毒(SARS-CoV - 2)的人群免疫力
  • DOI:
    10.1016/j.ebiom.2025.105760
  • 发表时间:
    2025-06-01
  • 期刊:
  • 影响因子:
    10.800
  • 作者:
    Mhairi J. McCormack;Sam Scott;Nicola Logan;Savitha Raveendran;Joseph Newman;Igor A. Santos;Dalan Bailey;Pablo R. Murcia;Emma C. Thomson;Margaret J. Hosie;Brian J. Willett
  • 通讯作者:
    Brian J. Willett

Dalan Bailey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dalan Bailey', 18)}}的其他基金

Viral entry at the human-animal interface; dissecting the pan-tropic nature of zoonotic viruses.
病毒进入人与动物的界面;
  • 批准号:
    BB/W006162/1
  • 财政年份:
    2022
  • 资助金额:
    $ 56.97万
  • 项目类别:
    Research Grant

相似国自然基金

声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
  • 批准号:
    82371973
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
  • 批准号:
    82371798
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
  • 批准号:
    82371141
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
  • 批准号:
    82371791
  • 批准年份:
    2023
  • 资助金额:
    49.00 万元
  • 项目类别:
    面上项目
MET通过MTOR介导的自噬调节肝癌免疫原性和治疗抗性的作用及机制研究
  • 批准号:
    31970696
  • 批准年份:
    2019
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
NLK磷酸化IRF2BP2对PD-L1表达调控的研究
  • 批准号:
    31900554
  • 批准年份:
    2019
  • 资助金额:
    15.0 万元
  • 项目类别:
    青年科学基金项目
信使RNA-m6A修饰对树突状细胞抗肿瘤免疫反应的调控机制研究
  • 批准号:
    31870890
  • 批准年份:
    2018
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
免疫卡控点B7-H1、B7-H3和B7-H4病理检测试剂的研制及其在肠癌组织多重染色分析的临床意义
  • 批准号:
    31700778
  • 批准年份:
    2017
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
CXCR2+MDSCs亚群在PD1/PDL1阻断治疗乳腺癌无效或抵抗中的作用和机制研究
  • 批准号:
    31770966
  • 批准年份:
    2017
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
SCAP/SREBP固醇代谢途径异常在胃癌PD-1hiCD8+耗竭性T细胞亚群形成中的作用机制及其逆转研究
  • 批准号:
    31770963
  • 批准年份:
    2017
  • 资助金额:
    25.0 万元
  • 项目类别:
    面上项目

相似海外基金

Innate immune factors governing restriction of human coronaviruses
控制人类冠状病毒限制的先天免疫因素
  • 批准号:
    10506519
  • 财政年份:
    2022
  • 资助金额:
    $ 56.97万
  • 项目类别:
Innate immune factors governing restriction of human coronaviruses
控制人类冠状病毒限制的先天免疫因素
  • 批准号:
    10673163
  • 财政年份:
    2022
  • 资助金额:
    $ 56.97万
  • 项目类别:
Structure-function relationships of the influenza virus RNA polymerase: influence on virulence, host restriction and innate immune responses
流感病毒RNA聚合酶的结构-功能关系:对毒力、宿主限制和先天免疫反应的影响
  • 批准号:
    MR/R009945/1
  • 财政年份:
    2018
  • 资助金额:
    $ 56.97万
  • 项目类别:
    Research Grant
Regulation of Rotavirus Replication, Virulence, and Host Range Restriction by the Innate Immune System
先天免疫系统对轮状病毒复制、毒力和宿主范围限制的调节
  • 批准号:
    9308428
  • 财政年份:
    2017
  • 资助金额:
    $ 56.97万
  • 项目类别:
Regulation of Rotavirus Replication, Virulence, and Host Range Restriction by the Innate Immune System
先天免疫系统对轮状病毒复制、毒力和宿主范围限制的调节
  • 批准号:
    10091389
  • 财政年份:
    2017
  • 资助金额:
    $ 56.97万
  • 项目类别:
The interplay between TRIM5alpha and autophagy in the activation of the innate immune response to HIV-1
TRIM5alpha 和自噬在激活 HIV-1 先天免疫反应中的相互作用
  • 批准号:
    350827
  • 财政年份:
    2016
  • 资助金额:
    $ 56.97万
  • 项目类别:
    Operating Grants
Analysis of the innate immune receptor NOD1 as a novel cause for the development of the intrauterine fetal growth restriction
分析先天免疫受体 NOD1 作为胎儿宫内生长受限的新原因
  • 批准号:
    15K19656
  • 财政年份:
    2015
  • 资助金额:
    $ 56.97万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Analysis of the innate immune receptor NOD1 and its ligands as a novel cause for the development of the intrauterine fetal growth restriction
先天免疫受体 NOD1 及其配体作为宫内胎儿生长受限发生的新原因的分析
  • 批准号:
    24659509
  • 财政年份:
    2012
  • 资助金额:
    $ 56.97万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Dendritic Cell Restriction and Innate Immune Sensing of HIV Infection
HIV 感染的树突状细胞限制和先天免疫感应
  • 批准号:
    7841122
  • 财政年份:
    2010
  • 资助金额:
    $ 56.97万
  • 项目类别:
Innate Restriction Factor Modulation of Retrovirus-specific Humoral Immunity
逆转录病毒特异性体液免疫的先天限制因子调节
  • 批准号:
    7988826
  • 财政年份:
    2010
  • 资助金额:
    $ 56.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了